Inspire Medical Systems (NYSE:INSP) Downgraded to “Underperform” Rating by Bank of America

Inspire Medical Systems (NYSE:INSP) was downgraded by investment analysts at Bank of America from a “neutral” rating to an “underperform” rating in a research report issued on Friday, Marketbeat reports. They presently have a $39.00 target price on the stock. Bank of America‘s price objective indicates a potential downside of 12.98% from the stock’s current price.

A number of other research analysts have also recently commented on the stock. Weiss Ratings cut shares of Inspire Medical Systems from a “sell (d+)” rating to a “sell (d)” rating in a research note on Wednesday, May 6th. Stifel Nicolaus cut their target price on shares of Inspire Medical Systems from $70.00 to $65.00 and set a “buy” rating for the company in a research note on Tuesday, May 5th. Evercore set a $55.00 target price on shares of Inspire Medical Systems in a research note on Tuesday, May 5th. UBS Group set a $67.00 target price on shares of Inspire Medical Systems in a research note on Friday, February 13th. Finally, Jefferies Financial Group cut their target price on shares of Inspire Medical Systems from $81.00 to $66.00 and set a “hold” rating for the company in a research note on Thursday, February 12th. Four equities research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Inspire Medical Systems currently has a consensus rating of “Hold” and an average price target of $81.84.

Inspire Medical Systems Stock Up 1.5%

Shares of INSP opened at $44.82 on Friday. The stock has a market cap of $1.29 billion, a price-to-earnings ratio of 9.98, a P/E/G ratio of 4.56 and a beta of 0.83. Inspire Medical Systems has a 12 month low of $39.61 and a 12 month high of $148.55. The company has a 50-day moving average price of $51.93 and a two-hundred day moving average price of $76.52.

Inspire Medical Systems (NYSE:INSP) last announced its quarterly earnings results on Monday, May 4th. The company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.38. The firm had revenue of $204.58 million during the quarter, compared to analysts’ expectations of $200.04 million. Inspire Medical Systems had a net margin of 14.33% and a return on equity of 10.35%. The company’s revenue for the quarter was up 1.6% compared to the same quarter last year. During the same quarter last year, the company earned $0.10 earnings per share. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. Equities research analysts expect that Inspire Medical Systems will post 0.91 EPS for the current fiscal year.

Institutional Trading of Inspire Medical Systems

A number of hedge funds and other institutional investors have recently modified their holdings of INSP. Wellington Management Group LLP acquired a new stake in shares of Inspire Medical Systems in the fourth quarter valued at approximately $203,929,000. M&T Bank Corp acquired a new stake in shares of Inspire Medical Systems in the fourth quarter valued at approximately $85,871,000. Deerfield Management Company L.P. increased its holdings in shares of Inspire Medical Systems by 648.4% in the third quarter. Deerfield Management Company L.P. now owns 1,047,694 shares of the company’s stock valued at $77,739,000 after purchasing an additional 907,694 shares in the last quarter. Morgan Stanley increased its holdings in shares of Inspire Medical Systems by 179.5% in the fourth quarter. Morgan Stanley now owns 1,259,762 shares of the company’s stock valued at $116,188,000 after purchasing an additional 809,121 shares in the last quarter. Finally, Fuller & Thaler Asset Management Inc. acquired a new stake in shares of Inspire Medical Systems in the fourth quarter valued at approximately $61,619,000. Institutional investors and hedge funds own 94.91% of the company’s stock.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.